Abeona Therapeutics Inc. Common Stock (ABEO) — Analysis Summary
Abeona Therapeutics Inc. Common Stock (ABEO) has a market cap of $399.54M with year-over-year revenue growth of +66.3%. Net margin stands at 1223.1%. The stock trades at a P/E ratio of 6.0.
Key Takeaways
- Revenue changed +66.3% year-over-year
- Net margin of 1223.1%
- P/E ratio of 6.0
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, ABEO posted revenue growth of +66.3% and trades at a P/E of 6.0.
Abeona Therapeutics Inc. Common Stock (ABEO)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -26.0x — earnings do not cover interest payments
Revenue fell 100.0% vs the prior period.
Operating cash flow is negative while net income remains positive.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
226
Headquarters
CLEVELAND, OH
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.